SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TITAN PHARMACEUTICAL (TTP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: John McCarthy12/12/2005 8:21:42 AM
   of 362
 
Titan Announces that Vanda Pharmaceuticals Initiates Phase III Clinical Trial of Iloperidone

SOUTH SAN FRANCISCO, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (Amex: TTP) today announced that Vanda Pharmaceuticals Inc. has initiated a Phase III clinical study of iloperidone, Titan's proprietary antipsychotic agent licensed to Vanda and in development for the treatment of schizophrenia and related disorders.

The study is designed as a randomized, double blind, controlled, three arm study. Patients in this
multi-center study will receive iloperidone, placebo, or an active control.

The study is designed to assess the efficacy, safety and tolerability of iloperidone in schizophrenic patients in acute exacerbation. The primary endpoint of the study is the reduction in the symptoms of schizophrenia as
assessed by the Positive and Negative Symptom Scale (PANSS).
Iloperidone is a novel 5HT2/D2 antagonist, antipsychotic agent in development for schizophrenia and other disorders.

prnewswire.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News